REPLIGEN CORP — Director's Dealing 2019

Mar 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2019-02-28

Reporting Person: Hunt Anthony (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-28	Common Stock	A	22681	$0.00	Acquired	250132	Direct
2019-02-28	Common Stock	S	7475	$59.01	Disposed	242657	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-28	Stock Option (Right to Buy)	$59.52	A	21651	Acquired	2029-02-28	Common Stock (21651)	Direct

Footnotes

F1: Mr. Hunt was awarded 22,681 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: Sale of 7,475 shares in the open market to cover tax liability resulting from the release of restricted stock units.

F3: $59.01 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.75 to $59.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: One third of the stock options will vest and become exercisable annually on February 28, 2020, February 28, 2021 and February 28, 2022.